Wall Street analysts expect TESARO Inc (NASDAQ:TSRO) to post $88.34 million in sales for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for TESARO’s earnings. The highest sales estimate is $96.40 million and the lowest is $76.60 million. TESARO posted sales of $48.02 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 84%. The business is expected to report its next quarterly earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that TESARO will report full year sales of $260.83 million for the current financial year, with estimates ranging from $247.90 million to $267.70 million. For the next year, analysts anticipate that the company will post sales of $356.40 million, with estimates ranging from $283.10 million to $411.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for TESARO.
TESARO (NASDAQ:TSRO) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share for the quarter, beating the consensus estimate of ($2.62) by $0.13. The business had revenue of $64.40 million for the quarter, compared to the consensus estimate of $71.84 million. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The business’s quarterly revenue was down 54.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.47) earnings per share.
Several research firms have recently weighed in on TSRO. Evercore ISI downgraded TESARO to an “outperform” rating in a research report on Tuesday. BidaskClub upgraded TESARO from a “buy” rating to a “strong-buy” rating in a research report on Friday. Cantor Fitzgerald downgraded TESARO from an “overweight” rating to a “neutral” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $69.00 price objective on shares of TESARO in a research report on Monday, December 3rd. Finally, Wells Fargo & Co downgraded TESARO from an “outperform” rating to a “market perform” rating in a research report on Monday, December 3rd. Fifteen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $78.18.
A number of hedge funds have recently bought and sold shares of the business. US Bancorp DE grew its stake in shares of TESARO by 163.5% in the third quarter. US Bancorp DE now owns 3,940 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 2,445 shares in the last quarter. New Jersey Better Educational Savings Trust acquired a new stake in shares of TESARO in the third quarter valued at $234,000. Janney Montgomery Scott LLC acquired a new stake in shares of TESARO in the second quarter valued at $257,000. Pacer Advisors Inc. acquired a new stake in shares of TESARO in the third quarter valued at $273,000. Finally, BTG Pactual Global Asset Management Ltd acquired a new stake in shares of TESARO in the second quarter valued at $277,000.
NASDAQ TSRO opened at $73.95 on Friday. The company has a market capitalization of $4.06 billion, a PE ratio of -8.06 and a beta of 1.49. TESARO has a 1-year low of $23.41 and a 1-year high of $85.48. The company has a current ratio of 3.40, a quick ratio of 2.83 and a debt-to-equity ratio of 3.74.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Featured Story: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.